| Gastric cancer(GC)is a common malignant tumor of the digestive system,with its low care rate and fatality rate ranking the third among malignant tumors.Risk factors contributing to GC include smoking,drinking,eating habits and helicobacter pylori infection.Intensive research on GC-related gene abnormality is of great significance for the treatment of GC.With the improvement of molecular technology,breakthroughs have been achieved in cancer research.Traditional Chinese medicine has a long history and solid theoretical basis for cancer treatment with abundant cases.Traditional Chinese physicians have proposed to extract anti-cancer drugs from natural Chinese medicinal herb.Banxia Xiexin decoction is used to treat chronic gastritis,gastric ulcer,gastric cancer,and other digestive system tumors.The first case was recorded in Treatise on Febrile Diseases by Zhang Zhongjing,which used Banxia Xiexin decoction to treat epigastric disease and achieved satisfactory results.Banxia Xiexin decoction can directly or indirectly act on the digestive tract to treat various digestive diseases.Non-coding RNA(ncRNA)is transcribed from genomes but cannot encode protein.Although it cannot encode protein,ncRNA has complex functions at the RNA level.For example,it regulates the expression of oncogenes and tumor suppressor genes and can be used as a potential marker for tumor diagnosis.Long non-coding RNA refers to ncRNA with over 200 nucleotides,which can be obtained either by transformation of protein-coding gene sequence into non-coding gene or by insertion of transposons.The ncRNA human TUC.338 sequence is 590bp in length and located on chromosome 12,which has recently become a research focus on disease molecular mechanism.Some studies have shown that it can promote the onset and development of tumors.The primary purpose of the study is to observe the clinical effects of Banxia Xiexin decoction combined with chemotherapy treating patients with advanced GC.This paper is divided into two parts.The first part evaluates the quality of life,adverse reactions to chemotherapy and other indexes for patients treated with Banxia Xiexin decoction combined with chemotherapy,which provides theoretical basis for the clinical treatment of GC.The second part explores the molecular mechanisms of Banxia Xiexin decoction in treating GC through in vitro experiment.Part Ⅰ Clinical research[Objective]The purpose of this part is to explore the clinical effects of Banxia Xiexin decoction in treating gastric cancer(GC)and the factors influencing patients’ survival,thus providing evidence for its application based on evidence-based medicine.[Methods]Sixty patients with advanced gastric cancer were enrolled and divided into 2 groups based on different treatment methods.The control group were treated with standard chemotherapy recommended by Gastric Cancer Diagnosis and Treatment Specification(2018 edition)and NCCN Clinical Practice Guidelines for Gastric Cancer(2018 edition).The treatment group were additionally treated with Banxie Xiexin decoction.Effects of Banxia Xiexin decoction on the quality of life for GC patients receiving chemotherapy were quantified by EORTC Quality of Life Questionnaire-Core 30(QLQ-C30).Adverse reactions,one-year survival and objective remission rate were also analyzed.[Results]①No statistical difference was observed between the two groups in demographic data(P>0.05).②Before treatment,no significance difference was observed in the quality of life and serum markers between the two groups(P>0.05).After treatment,the treatment group achieved higher scores of function and general health status than the control group,with lower scores of symptoms(P<0.05).③Compared with the control group,the clinical effective rate and disease control rate of the treatment group had no significant difference(P>0.05).④The incidence of vomiting,diarrhea,leukopenia and hemoglobinemia were lower(P<0.05).No significance was observed in peripheral neurotoxicity(P<0.05).⑤No significance difference was observed in one-year survival between the two groups(P>0.05).[Conclusions]Banxia Xiexin decoction has good clinical effects in treating gastric cancer and can reduce the incidence of adverse reactions,which is worth promoting.Part Ⅱ Infratest[Objective]The purpose of this part is to investigate the expression of long non-coding RNATUC.338(LncRNATUC.338)in gastric cancer tissues and cells,and to explore whether Banxia Xiexin decoction(BXD)can inhibit invasion and metastasis of human GC cells through regulating LncRNA TUC.338.[Methods]Gene chip was used to measure the differential expression of gene profiles in gastric cancer and adjacent tissues.The expression of lncRNA TUC.338 in AGS cells was measured by qRT-PCR.Lentivirus transfection was used to knock down LncRNA TUC.338 in human GC AGS cells.The effects of LncRNA TUC.338 knockdown on invasion and metastasis were evaluated by Wound healing assay and Transwell test.The expression of epithelial-to-mesenchymal transition(EMT)related protein in LncRNA TUC.338-knockdown AGS cells was analyzed by Western blot.MTT assay was used to investigate the effects of BXD(50,100,150,200,250 and 300 mg/ml)on the proliferation of human GC AGS cells.After treating the cells with BXD of different concentrations(50,100 and 150 mg/ml)for 24 hours,Wound healing assay and Transwell test were applied to evaluate the effects of BXD on the invasion and metastasis capacity of AGS cells,qRT-PCR was also used to analyze the effects of BXD on LncRNA TUC.338.[Results]LncRNA TUC.338 had high expression levels in both GC tissues and AGS cells.LncRNA TUC.338 knockdown reduced the invasion and metastasis capacity of human GC AGS cells,increased the expression of EMT-related protein E-cadherin and decreased the expression of N-cadherin and Vimentin.BXD significantly inhibited the invasion and metastasis of human GC AGS cells,and can reduce the expression of LncRNA TUC.338 in AGS cells.[Conclusions]BXD significantly inhibited the invasion,metastasis and epithelial-mesenchymal transition of human GC AGS cells.The molecular mechanism may be related to the decreased expression of LncRNA TUC.338. |
PDF Full Text Request